Verrica Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $14.7M+187.0% YoYTTM through 30 Jun 2025
Net Income -$31.2MTTM through 30 Jun 2026
Free Cash Flow -$13.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 89.2% |
| EBITDA Margin | -192.1% |
| Operating Margin | -193.4% |
| Net Margin | -212.1% |
Returns
-86.6%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.02x
Net Debt-$20.6Mnet cash position
Cash & Equivalents$11.2M
Quality Metrics
Altman Z-Score-13.83
Piotroski F-Score4 / 9
FCF Margin-90.8%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $35.6M
Diluted EPS-$1.74TTMFY2025: $-1.68
Dividend
No dividend
Capital Allocation
R&D Spend$14.6M
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| U.S. YCANTH Product | $4.3M | +25.4% | View detailsStrong commercial uptake continues with sales force expanding from 44 to approximately 50 representatives in 2026. |
| License and Collaboration | $733K | View detailsTorii is funding the first $40 million of Phase 3 common warts program costs. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.